日本医科大学医学会雑誌
Online ISSN : 1880-2877
Print ISSN : 1349-8975
ISSN-L : 1349-8975
2 巻, 4 号
選択された号の論文の10件中1~10を表示しています
グラビア
シリーズ カラーアトラス
綜説
  • 横井 公良, 田中 宣威, 石川 紀行, 瀬谷 知子, 大秋 美治, 田尻 孝
    2006 年 2 巻 4 号 p. 186-191
    発行日: 2006年
    公開日: 2006/11/15
    ジャーナル フリー
    Gastrointestinal stromal tumor (GIST) is generally defined as a mesenchymal tumor that consisits of spindle-shaped or epitheloid cells, originates in the gastrointestinal tract, and immunohistochemically expresses c-kit and/or CD34, regardless of myogenic and neurogenic markers. Gastrointestinal mesenchymal tumors are generally diagnosed as the submucosal tumors. Most of these tumors were histologically diagnosed as myogenic or neurogenic tumors. However, with the development of immunohistochemistry in the 1980s, we were able to clearly distinguish between myogenic tumors and neurogenic tumors. This new ability also resulted in the development of a new concept of the tumor that could not be classified into either of them. The tumor is, in fact, GIST. However, a quarter of a century was required for the concept and the treatment of GIST to be established. Because of four breakthroughs (1. the development of immunohistochemistry, 2. the classification in Ackerman's Surgical Pathology, 3. the derivation from interstitial cells of Cajal and 4. the high efficacy of imatinib mesylate) during this time, the concept of GIST has changed greatly. On the other hand, the resistance to imatinib in GIST has gradually increased, and new problems have arisen. The further development of drugs (five kinds of drugs such as SU 11248 are undergoing clinical trials) is awaited.
  • 吾妻 安良太
    2006 年 2 巻 4 号 p. 192-201
    発行日: 2006年
    公開日: 2006/11/15
    ジャーナル フリー
    Idiopathic pulmonary fibrosis (IPF) is a devastating and fatal disease of unknown etiology. Survival of IPF is estimated at 3 to 4 years from first medical assessment for idiopathic interstitial pneumonias (IIPs). Currently, available therapies for IPF include corticosteroid and immunosuppressant for anti-inflammatory actions unfortunately no improvements were noted for the survival of IPF. Recently, several clinical studies report on the antifibrotic outcomes for new agents of IPF. Pirfendione, Interferon (IFN)-γ, and N-acetylcysteine (NAC) are promising agents for IPF. We confirmed the efficacy of pirfenidone as a significant inhibitor for the deterioration of pulmonary functions and for decreasing the number of patients with acute exacerbations during a well designed, double blind placebo controlled randomized clinical trial in Japan. Furthermore, we adopted new methods for assessing dynamic pulmonary function by measuring minimum values of desaturation during 6 minutes walking at constant speed. Interstitial pneumonia in patients with Hermansky-Pudlak syndrome has been treated with pirfenidone in US. Pirfenidone successfully prevents worsening of %FVC for patients with %FVC>60%, but not for the group %FVC≤60%. Treatment with IFN-γ for IPF has been conducted in North America, but IFN-γ could not improve progression-free survival for the intent-to-treat group. However, IFN-γ significantly decreased the mortality ratio in patients with %FVC>60%. Recently, the evaluation of effective drugs for IPF has focused on dynamic pulmonary functions such as 6 minutes walk test, as pathological evaluation of IIPs is not recognized as a gold standard for estimating survival of patients with IPF. In this review, we introduce new strategies for the evaluation, and compounds for the treatment of IPF.
症例から学ぶ
  • 肥田 道彦, 斉藤 卓弥, 大久保 善朗
    2006 年 2 巻 4 号 p. 202-205
    発行日: 2006年
    公開日: 2006/11/15
    ジャーナル フリー
    We report a case of anorexia nervosa with familial idiopathic basal ganglia calcification (IBGC, Fahr's disease). A 30-year-old woman with anorexia nervosa was brought to the Department of Critical Care Medicine because of severe weight loss and dehydration. Imaging studies revealed bilaterally symmetrical calcifications in the caudate nucleus, putamen, globus pallidus, and thalamus, and Fahr's disease was diagnosed. Fahr's disease sometimes has comorbid psychiatric conditions, such as schizophrenia and personality changes, but this is the first case of Fahr's disease with anorexia nervosa. This case illustrates the importance of comprehensive medical assessment for psychiatric patients admitted for the first time.
症例報告
話題
feedback
Top